1 Oxycodone is a strong opioid agonist that is currently available in immediaterelease ( IR) formulations for the treatment of moderate to severe pain. Recently, controlled-release (CR) oxycodone tablets were developed to provide the benefits of twice-a-day dosing to patients treated with oxycodone. The purpose of this investigation was to develop and validate a pharmacokinetic model for CR oxycodone tablets in comparison with IR oxycodone solution. 2 Twenty-four normal male volunteers were enrolled in a single-dose, randomized, analytically blinded, two-way crossover study designed to compare the pharmacokinetics of two 10 mg CR oxycodone tablets with 20 mg IR oxycodone oral solution. Pharmacokinetic models describing the oxycodone plasma concentration vs time profiles of CR tablets and IR solution were derived using NONMEM version IV. The predictive performance of the models was assessed by comparison of predicted oxycodone plasma concentrations with actual oxycodone plasma concentrations observed in a separate group of 21 volunteers who received repeated doses of IR and CR oxycodone for 4 days. 3 The unit impulse disposition function of oxycodone was best described by a one-compartment model. Absorption rate of the IR solution was best described by a mono-exponential model with a lag time, whereas absorption rate of the CR tablet was best described using a bi-exponential model. The absorption profile of the CR tablets was characterized by a rapid absorption component (t 1/2 abs=37 min) accounting for 38% of the available dose and a slow absorption phase ( t 1/2 abs=6.2 h) accounting for 62% of the available dose. Two 10 mg tablets of oral CR oxycodone hydrochloride were 102.7% bioavailable relative to 20 mg of IR oxycodone hydrochloride oral solution. The population model derived after administration of a single dose accurately predicted both the mean and range of oxycodone concentrations observed during 4 days of repeated dosing. The mean prediction error was 2.7% with a coefficient of variation of 54%. 4 The absorption characteristics of CR oxycodone tablets should allow effective plasma concentrations of oxycodone to be reached quickly and for effective concentrations to be maintained for a longer period after dosing compared with the IR oral solution. The CR dosage form has pharmacokinetic characteristics that permit 12 hourly dosing.
Introduction
way, crossover study. None of the volunteers who received repeated doses participated in the single-dose study. The methods used in this repeated-dose study A recent survey of anaesthetists in Finland found parenteral oxycodone to be the most popular opioid for have been reported elsewhere [ 8] . premedication, postoperative pain relief, and sedation in intensive care units [1 ] . Similar to morphine, oxycodone is a potent opioid agonist with a dose Pharmacokinetic sampling dependent analgesic effect [2 ] , that has proven effective in relieving postsurgical [3 ] and cancer-related pain
Single dose During each treatment period, venous [ 4] . Side effects that have been observed following blood samples were obtained immediately before study oxycodone administration are similar to those associated drug was administered (0 h) and at the following times with other strong opioids.
after dosing: 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, Pharmacokinetic studies have revealed that after oral 3, 3.5, 4, 6, 8, 10, 12, 18, 24, 30 , and 36 h. Plasma administration, oxycodone is rapidly absorbed to prooxycodone concentrations were analysed by GC/MS duce an initial peak plasma oxycodone concentration using naltrexone as the internal standard. The quantifiin about 2 h [ 5, 6 ] . Once peak plasma concentrations cation limit of oxycodone in plasma samples was are reached, oxycodone concentrations rapidly decline, 0.2 ng ml−1, with standard curve linearity between with an apparent terminal half-life ranging from 3.0 to 0.2 ng ml−1 and 100 ng ml−1. Inter-day and intra-day 5.7 h [ 5, 7] . Because oxycodone is rapidly absorbed precision (expressed as per cent coefficient of variation) and quickly eliminated after oral administration, freranged from 0.4% to 9.9% for nominal standards quent dosing (every 4-6 h) is required to maintain ranging from 0.2 ng ml−1 to 100 ng ml−1. Oxycodone plasma concentrations within the therapeutic analgesic analysis was performed by The Purdue Frederick range.
Research Center, Yonkers, NY, USA. Recently, controlled-release oxycodone tablets have been developed to extend the duration of action of oral Repeated dosing Oxycodone plasma concentrations oxycodone and provide the benefits of 12 hourly dosing.
were determined immediately before the morning dose In the present study, the pharmacokinetics of oxycodone on days 2-4. In addition, serial blood samples for controlled-release tablets were characterized in comparioxycodone determination were taken for 36 h beginning son with that of an immediate-release oxycodone oral with the morning dose on day 4. Plasma oxycodone solution. Pharmacokinetic models describing the plasma concentrations were analysed as described for the singleconcentration vs time profiles of immediate-release and dose study. controlled-release oxycodone after a single dose are presented. The predictive performance of the models was evaluated by comparing the plasma concentrations Pharmacokinetic analysis predicted by the models with actual plasma concentrations measured after 4 days of repeated dosing.
The peak plasma concentration (C max ) and time to C max (t max ) were read directly from individual plasma concentration-time curves. Area under the concentration-time curve from 0 to 36 h (AUC (0, 36 h)) was calculated by Methods the trapezoidal method. The elimination rate constant (l z ) was calculated by measuring the slope of the linear Study design regression line (log concentration vs time) in the terminal elimination phase for each subject. The apparent Single dose A randomized, single-dose, analytically elimination half-life (t D,z ) was calculated from the rate blinded, two-way crossover design in 24 healthy, fasting, constant. Differences in parameter estimates for the two male volunteers was used to compare the pharmacodosage forms were tested by analysis of variance kinetics of two 10 mg controlled-release oxycodone (ANOVA) appropriate to the crossover design. All tablets (OxyContin@, The Purdue Frederick Company, analyses were conducted as two-sided tests with alpha Norwalk, CT) with 20 mg of oxycodone administered equal to 0.05. The SASB (SAS Institute, Carey, NC) as an immediate-release oral solution (Roxicodone@, statistical package was used for all ANOVA calculations. Roxane Laboratories, Columbus, OH ). The two treatment phases were separated by a 1 week washout interval. This study was approved by the ethics comPharmacokinetic modelling mittee of the contract research organization Hazelton Wisconsin, Inc. All subjects provided written informed
The plasma concentration-time profiles were characconsent before participating in the study.
terized with the following general pharmacokinetic model: Repeated dosing Twenty-one healthy volunteers received one 10 mg controlled-release oxycodone tablet C p =f (t)1g(t) (1) every 12 h and 5 ml of a 5 mg 5 ml−1 immediate-release oxycodone oral solution every 6 h for 4 days in a where C p is the plasma concentration at time t, f (t) is the absorption model, g(t) is the unit impulse disposition randomized, analytically blinded, multiple-dose, two-function (i.e. the concentration vs time profile observed difference in number of parameters between the two models. A decrease of more than 6.6 in −2LL is after a unit intravenous dose), and * denotes convolution. significant at the P<0.01 level. Disposition model The unit impulse disposition function was assumed to be the same for the immediate-release Model development oral solution and the controlled-release tablet and was characterized by a sum of exponentials:
The models were fitted to the data using the nonlinear regression program NONMEM version IV [9, 10] .
Data were analysed using population analysis techniques. The population analysis technique recognizes where A i and a i are the coefficients and exponents of that repeated measures are taken from each individual. the unit impulse disposition function, respectively. The population pharmacokinetic model incorporates subject-specific random effects to characterize the differAbsorption model The absorption model was assumed ences in response between individuals and provides to be different for the two preparations. It was assumed estimates of the inter-individual variability in the that the absorption after administration of the immediparameters of the pharmacokinetic model. The popuate-release oral solution is rapid and could be described lation mean pharmacokinetic parameters obtained by a simple first order absorption process with a lag describe the response in the typical (mean) individual. time: [ 5, 7] .
residual departure of log(Y ij ) from log(Cp ij ) is represented Various absorption models were evaluated for the by e ij . Values of e ij are assumed to be independently and controlled-release tablet, ranging from multi-exponential normally distributed, with mean zero and variance s2. absorption models (similar to equation 2 ) to combinations of multi-exponential and zero-order absorption
Inter-individual variance model The inter-individual models. Absorption of oxycodone from the controlledvariability in the pharmacokinetic parameters was release tablets was best described by the following modelled according to an exponential variance model bi-exponential absorption model:
with the assumption that the pharmacokinetic param-
where F rel is the relative bioavailability of oxycodone in where p i is the vector of pharmacokinetic parameters of the controlled-release tablet compared to the immediatethe ith individual, h is the vector of population mean release solution, k c1 and k c2 are the two first-order pharmacokinetic parameters, and exp(g i ) expresses the apparent absorption rate constants for controlled-release random difference between h and p i . Values of g i are oxycodone, and f 1 denotes the fraction of dose absorbed assumed to be independently multi-variate normally via the absorption process controlled by the rate distributed, with mean zero and diagonal varianceconstant k c1
. The fraction of the dose absorbed via the covariance matrix V with diagonal elements (v 1 2, … , absorption process controlled by the rate constant k c2 v m 2). The values of the population parameters h, s2, is represented by (1−f 1 ). and V were estimated using the so-called first order The parametric absorption model for the controlledmethod in NONMEM. release tablet was compared with a nonparametric model derived from deconvolution of the plasma concentrations observed after administration of the Model validation To evaluate the predictive performance of the models derived from single-dose adminiscontrolled-release tablet and the unit impulse disposition function derived from the immediate-release solution.
tration of immediate-release and controlled-release oxycodone, the plasma concentrations of oxycodone The nonparametric absorption model was represented by a step-wise input model, one step for each interval after repeated administration for 4 days were compared with the concentrations predicted by the models. The between the following time points: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, 24, and 36 h.
plasma oxycodone concentrations at 108 h after the start of treatment (last sample) were not included in Model selection was based on the Log Likelihood criterion (P<0.01) and visual inspection of the fits. The the analysis because measurable concentrations were only observed in a few individuals. Oxycodone plasma difference in −2 times the Log of the Likelihood (−2LL) between a full and reduced model is asymptoticoncentrations in the remainder of the subjects were below the quantification limit of the assay, and inclusion cally x2 distributed with degrees of freedom equal to the of these samples would have resulted in a biased height and weight were 179 cm (range 162-191) and 76 kg (range 63-91), respectively. estimate of the mean prediction error.
The prediction error was calculated to evaluate how well the population pharmacokinetic models predicted the population mean response after 4 days of continuous Pharmacokinetic analysis administration. The log prediction error for a specific measurement was defined as:
Relative to the immediate-release solution, controlled-
release oxycodone was 102.7% bioavailable. Based on the 90% confidence interval for the AUC (0, 36 h) where Y ij is the jth measured concentration in the ith ratio's of the controlled-release tablet and immediate individual and Cp is the population mean concentration release solution (89.5-115.9%), the two formulations predicted by the pharmacokinetic model. The population were considered equally bioavailable (Table 1 ). The mean response was obtained from a Monte Carlo AUC(0, 36 h) was not significantly different (P >0.05) simulation of 2500 subjects using the parameter estimates for the two dosage forms. However, differences in mean (mean and variance) of the population model. Cp for C max , t max , and apparent t D,z were significant (P= each time point was calculated directly from the 0.0001). Figure 1 illustrates the mean oxycodone simulated data as the logarithmic mean of all simulated plasma concentration vs time curve for the two dosage concentrations. An estimate of the bias of the model forms. As would be expected with a controlled-release predictions was given by the average L PE. The variance formulation, the peak oxycodone plasma concentration of L PE indicates the variability of the measured was lower after the controlled-release tablet than after concentrations around the population mean prediction.
the immediate-release solution and plasma levels The definition of prediction error according to equation declined less rapidly after the peak plasma concen-7 was preferred over the percentage prediction error, tration was reached. (Y ij −Cp ij )100/Cp ij , because the individual plasma concentration measurements and predictions tend to follow a logarithmic distribution rather than a normal distribution.
The Monte Carlo simulation of 2500 subjects using the parameter estimates (mean and variance) of the population model was also used to evaluate how well the population model predicted the range of observed concentrations after repeated dosing for 4 days.
Results

Subjects
Of the 24 volunteers enrolled in the single-dose study, 23 completed both study phases and were included in Figures 2 and 3 show oxycodone concentrations predicted by pharmacokinetic models using the typical values of the pharmacokinetic parameters derived from Immediate-release The combination of a simple, firstorder absorption model (equation 3) and a monothe population analysis as well as the actual concentrations measured after administration of single doses exponential unit impulse disposition function (equation 2) best described the concentrations observed after of controlled-release and immediate-release oxycodone. Figure 2 displays the fit for the first 8 h, highlighting the administration of the immediate-release oral solution. This is consistent with the mean concentration profile absorption phase. Figure 3 shows the fit over the entire single-dose study period, highlighting the terminal observed in Figure 1 . For the final analysis, the disposition model was parameterized in CL/F and V d /F, elimination phase. The cumulative fraction of drug absorbed from the where CL denotes clearance, V d is volume of distribution at steady-state, and F is the bioavailability of the oral controlled-release tablet following administration of a single dose is shown in Figure 4 . The thick solid line solution. The actual bioavailability of the immediaterelease oral solution was not determined in this study represents the median fraction absorbed obtained from a Monte Carlo simulation of 2500 individuals using the because an intravenous reference dose was not evaluated.
Pharmacokinetic model
population mean pharmacokinetic parameters and their inter-individual variances. The interval in which 80% of the simulated data of the individuals lies (between the Controlled-release Various absorption models were 10th and 90th percentiles) is indicated by the thin evaluated for the controlled-release tablet, but only the solid lines. model that best described the data (as determined by
The bi-exponential absorption pattern of controlledthe Log Likelihood criterion and visual inspection) is release oxycodone corresponded closely with the absorppresented. Absorption of oxycodone from the controlledrelease tablets was best described by the bi-exponential absorption model described by equation 4. This model was preferred over a mono-exponential, zero-order drug input, or mono-exponential combined with zero-order drug input. The controlled-release data were best described using the same lag time as for the immediaterelease oral solution.
Results of the population analysis are presented in Table 2 . The inclusion of separate residual variance terms for the immediate-release solution and controlledrelease tablets in the analysis did not significantly improve the fit of the models. function with a one-compartment disposition model following for CL, 25% for V d , 105% for k a , 38% for F rel , 50% for k c1 , administration of the immediate-release oral solution. (b) fit of 48% for k c2 , 23% for f 1 , and 15% for the lag time. ‡s is the model linking the bi-exponential absorption function with approximately equal to the percentage of residual variability a one-compartment disposition model following administration of the controlled-release tablets. which is 25% for the population analysis. tion pattern derived using the non-parametric absorption model (deconvolution data not shown). The nonparametric absorption model, using 11 more parameters, resulted in only a minor improvement of the fit (6.1 points decrease in −2LL), confirming that the derived bi-exponential absorption model is a good description of the absorption profile of the controlledrelease tablet.
Predictive performance
The mean and variance of the prediction errors were −0.0061 and 0.291, respectively, for the immediate release solution and 0.0335 and 0.287 for the controlled release tablet. The exponent of the mean L PE indicates that compared with the actual mean plasma concentrations, predicted concentrations were on average 0.6% higher for the immediate-release solution and 3.3% lower for the controlled-release tablets. Figure 5 shows the comparison of the mean oxyco- done plasma concentrations observed during the 4 days Safety of repeated dosing and the population mean concentrations predicted by the Monte Carlo simulations using Seven subjects reported a total of 31 adverse experiences after taking controlled-release oxycodone, and 12 subthe parameters from the population analysis (all means are logarithmic means). Figure 6 shows the range of jects reported a total of 55 adverse experiences after receiving the immediate-release oxycodone solution concentrations predicted by the Monte Carlo simulations in comparison with the actual observed concen- (Table 3 ) . Most adverse experiences involved the gastrointestinal tract or central nervous system. None of the trations. The thin lines cover the region in which 90% of the simulated data lies (5th-95th percentile). The subjects required medical treatment for an adverse experience. There were no medically significant changes population model predicts the distribution of observed concentrations quite accurately. The simulated 5th in results of physical examinations or abnormal clinical laboratory findings attributed to study medication. percentile actually includes 9.7% of the observed concentrations for the immediate-release oral solution, There were no medically significant changes in vital signs observed during the study. whereas the simulated 95th percentile includes 93.8% of the observed concentrations (84% of the observed concentrations fall within the two lines). The values for the controlled-release tablets are 6.8% and 98.2%, respectively (92% of the observed concentrations fall Discussion within the two lines).
Pharmacokinetic parameter estimates were derived We have characterized the pharmacokinetics of oxycodone administered as a controlled-release tablet and by fitting the pharmacokinetic models to the concentration data observed after repeated administration.
compared it with immediate-release oxycodone oral solution. A simple one-compartment model with firstExcept for the apparent absorption rate constant of the immediate-release solution, all the pharmacokinetic order absorption best described the oxycodone plasma concentration vs time profile of the immediate-release parameters obtained after 4 days of repeated administration were similar to the parameters obtained after oral solution. Absorption of oxycodone from the immediate-release solution was rapid, resulting in a high initial single-dose administration. This is consistent with the ability of the pharmacokinetic model derived after a peak concentration. After the peak oxycodone concentration was reached, plasma concentrations declined single dose to predict plasma concentrations during 4 days of repeated dosing. The model fitting also revealed rapidly. The pharmacokinetic profile of immediate-release oxycodone obtained in this study was consistent with that the variability of the observed concentrations around the predicted concentrations was similar after those that have been previously reported [11, 5] .
In the present study, oxycodone clearance (CL/F ) single-dose and repeated-dose administration, 47% and 53%, respectively.
following administration of the immediate-release solution was slightly higher (110 l h−1 ) than values concentrations for the population model. The population model not only characterizes the population mean reported by Pöyhiä et al.
[11 ] and Leow et al. [5] . However, the differences in oxycodone clearance between response, but also characterizes the variability in plasma drug concentrations between individuals by estimating this study and previous studies were found to be of no clinical significance when the data were adjusted for the inter-individual variability in the pharmacokinetic parameters. The characterization of the distribution of body weight (1.1-1.4 l kg−1 h−1 ).
The bioavailability of oxycodone in the controlledpharmacokinetic parameters in the patient population is crucial for the design of dosage regimens that will release tablets was equivalent to that of the immediaterelease oral solution. This is supported by the fact that ensure that most of the patients receive a safe and efficacious treatment. both the nonparametric analysis and the parametric analysis produced similar estimates of bioavailability for
The variability in plasma concentrations for both immediate-release and controlled-release oxycodone was controlled-release oxycodone relative to immediaterelease oxycodone (Tables 1 and 2 ). within the range expected for oral opioids. The average coefficients of variation of the plasma concentrations The absorption profile of the controlled-release tablet was best described using a bi-exponential absorption around the mean were approximately 47% after administration of a single dose and 53% after 4 days of repeated model, with a rapid initial absorption component (t D abs=37 min) accounting for 38% of the available dosing. There was no difference in the overall variability between the two formulations. Population analysis dose followed by a slow absorption phase (t D abs=6.2 h) accounting for 62% of the available dose.
indicated that about 70% of the variability in plasma oxycodone concentrations could be attributed to interThe absorption rate constant for the slow absorption phase of controlled-release oxycodone was smaller than individual variability in pharmacokinetic parameters. The greatest variance occurred in those parameters the elimination rate constant of oxycodone observed from the immediate-release oral solution data.
describing the absorption processes. The Monte Carlo simulations showed that the population model derived Consequently, a slower terminal decline in oxycodone plasma concentrations was observed with the controlledfrom the single dose data accurately predicts the distribution of oxycodone plasma concentrations during release tablets compared with the immediate-release solution. This should allow for a prolonged duration of repeated dosing for four days. The fact that the population model is able to predict both the mean and analgesic activity. At the same time, the initial rapid absorption phase for controlled-release oxycodone prorange of oxycodone plasma concentrations during 4 days of consecutive dosing clearly supports the validity duced a rapid rise in oxycodone plasma concentrations that should ensure a rapid onset of action.
and usefulness of the proposed population model and estimated population parameters. Lower peak oxycodone concentrations after dosing with controlled-release oxycodone were associated with Comparable plasma concentration profiles were obtained with 10 mg controlled-release tablets every fewer side effects compared with dosing with immediaterelease solution at the same total dose. However, these 12 h and 5 mg immediate-release solution every 6 h, suggesting that either formulation could be used for differences were not statistically significant in the data we examined, and whether or not higher peak plasma long-term pain management. However, there are fewer peak/trough oscillations and less fluctuation in plasma concentrations observed with immediate-release oxycodone were the cause of the increased number of side concentrations during steady-state dosing with the controlled-release tablets. The controlled-release formueffects can not be determined.
The ability of a simple bi-exponential absorption lation could also offer the convenience of twice-daily administration. model to characterize the plasma oxycodone profile after administration of the controlled-release tablet is
In conclusion, the pharmacokinetics of a newly developed controlled-release oxycodone tablet have been confirmed by the good fit to the data (Figures 2 and 3 ) and the close agreement between the bi-exponential characterized and compared with an immediate-release oral solution. The absorption characteristics of the absorption model and the step-wise input profile determined nonparametrically by deconvolution. The controlled-release tablet should allow effective plasma concentrations of oxycodone to be reached quickly, and validity of the proposed pharmacokinetic models is also confirmed by the ability of the models to predict the for effective concentrations to be maintained for a longer period after dosing compared with an immediate-release plasma concentrations in a group of different subjects during 4 days of consecutive dosing with the immediateoral formulation, thus allowing dosing every 12 h. release oral solution (5 mg every 6 h) and controlled- tration of each of the dosage forms, the predictive performance of the proposed models is very good, with a bias of less than 3.5% in predictions of mean References oxycodone concentrations based on parameter estimates from the population analysis. Figure 5 shows the close
